HOMERUS: A Local, Open Label, Multicentre, Phase IIIB Study, Investigating Subcutaneous Trastuzumab Administered at Home With Single Injection Device in Patients With HER2-Positive Early Breast Cancer
Phase of Trial: Phase III
Latest Information Update: 12 Jun 2019
Price : $35 *
At a glance
- Drugs Trastuzumab (Primary)
- Indications Adenocarcinoma; Early breast cancer; Male breast cancer
- Focus Adverse reactions; Registrational
- Acronyms HOMERUS
- Sponsors Roche
- 07 Aug 2018 Status changed from active, no longer recruiting to completed.
- 02 May 2017 Planned End Date changed from 1 Jul 2018 to 6 Jul 2018.
- 02 May 2017 Planned primary completion date changed from 1 Jul 2018 to 6 Jul 2018.